Dual Trigger with hCG Plus GnRHa for Final Oocyte Maturation in PGT-A Cycles Results in Similar Euploidy Rates when Compared to hCG-Only Trigger.
Dual trigger
Euploidy
Preimplantation genetic screening
hCG trigger
Journal
Reproductive sciences (Thousand Oaks, Calif.)
ISSN: 1933-7205
Titre abrégé: Reprod Sci
Pays: United States
ID NLM: 101291249
Informations de publication
Date de publication:
08 2022
08 2022
Historique:
received:
28
12
2021
accepted:
15
04
2022
pubmed:
28
4
2022
medline:
9
8
2022
entrez:
27
4
2022
Statut:
ppublish
Résumé
Factors that may have an effect on euploidy rate of blastocysts have been investigated thoroughly in the literature. We aimed to assess whether dual trigger alters the ploidy chance of a blastocyst in preimplantation genetic screening for aneuploidy (PGT-A) cycles. This retrospective cohort study was conducted in a total of 385 PGT-A cycles at a single tertiary center for various indications. Final oocyte maturation was triggered using human chorionic gonadotropin (hCG) or the combination of hCG and gonadotropin-releasing hormone agonists (GnRHa) (dual trigger). Participants were divided based on triggering method and all demographic and clinical characteristics of the patients were compared. Final oocyte maturation was triggered in 143 cycles with hCG (37.1%), and in 242 cycles with dual trigger (62.9%). The duration of stimulation was shorter in the dual trigger arm compared to the hCG trigger group (10.0 ± 1.6 vs. 9.4 ± 1.4 days, p ≤ .001). Euploidy rates per blastocyst tested were 23.4% and 26.1% respectively for hCG and dual trigger groups without significance. Similar rates of euploidy were noted, even after age stratification. There was no significant difference between the groups regarding positive pregnancy result and ongoing pregnancy rates (p = .779 vs. p = .188). Although dual triggering, compared to hCG triggering, does not provide an additional superiority on blastocyst euploidy rate, further studies in women with different infertility etiology are needed to specifically evaluate the impact of triggering method on ploidy rates.
Identifiants
pubmed: 35476351
doi: 10.1007/s43032-022-00954-7
pii: 10.1007/s43032-022-00954-7
doi:
Substances chimiques
Chorionic Gonadotropin
0
Gonadotropin-Releasing Hormone
33515-09-2
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
2265-2271Informations de copyright
© 2022. Society for Reproductive Investigation.
Références
Demko ZP, et al. Effects of maternal age on euploidy rates in a large cohort of embryos analyzed with 24-chromosome single-nucleotide polymorphism-based preimplantation genetic screening. Fertil Steril. 2016;105(5):1307–13.
doi: 10.1016/j.fertnstert.2016.01.025
Ding N, et al. Dual trigger of final oocyte maturation with a combination of GnRH agonist and hCG versus a hCG alone trigger in GnRH antagonist cycle for in vitro fertilization: a systematic review and meta-analysis. Eur J Obstet Gynecol Reprod Biol. 2017;218:92–8.
doi: 10.1016/j.ejogrb.2017.09.004
Castillo JC, et al. Gonadotropin-releasing hormone agonist ovulation trigger-beyond OHSS prevention. Ups J Med Sci. 2020;125(2):138–43.
doi: 10.1080/03009734.2020.1737599
Wu Q, et al. Dosage of exogenous gonadotropins is not associated with blastocyst aneuploidy or live-birth rates in PGS cycles in Chinese women. Hum Reprod. 2018;33(10):1875–82.
doi: 10.1093/humrep/dey270
Hodes-Wertz B, et al. Changing ovarian stimulation parameters in a subsequent cycle does not increase the number of euploid embryos. Fertil Steril. 2015;103(4):947–53.
doi: 10.1016/j.fertnstert.2014.12.126
Labarta E, et al. Moderate ovarian stimulation does not increase the incidence of human embryo chromosomal abnormalities in in vitro fertilization cycles. J Clin Endocrinol Metab. 2012;97(10):E1987–94.
doi: 10.1210/jc.2012-1738
Thorne J, et al. Euploidy rates between cycles triggered with gonadotropin-releasing hormone agonist and human chorionic gonadotropin. Fertil Steril. 2019;112(2):258–65.
doi: 10.1016/j.fertnstert.2019.03.040
Jones BP, et al., Is oocyte maturity influenced by ovulation trigger type in oocyte donation cycles? Hum Fertil (Camb), 2019: p. 1–7.
Griffin D, et al. Dual trigger with gonadotropin-releasing hormone agonist and standard dose human chorionic gonadotropin to improve oocyte maturity rates. Fertil Steril. 2014;102(2):405–9.
doi: 10.1016/j.fertnstert.2014.04.028
Munne S, et al. Euploidy rates in donor egg cycles significantly differ between fertility centers. Hum Reprod. 2017;32(4):743–9.
doi: 10.1093/humrep/dex031
Zhao YY, Yu Y, Zhang XW. Overall blastocyst quality, trophectoderm grade, and inner cell mass grade predict pregnancy outcome in euploid blastocyst transfer cycles. Chin Med J (Engl). 2018;131(11):1261–7.
doi: 10.4103/0366-6999.232808
Lin MH, et al. Dual trigger with combination of gonadotropin-releasing hormone agonist and human chorionic gonadotropin significantly improves the live-birth rate for normal responders in GnRH-antagonist cycles. Fertil Steril. 2013;100(5):1296–302.
doi: 10.1016/j.fertnstert.2013.07.1976
Zhu H, et al. Dual trigger for final follicular maturation improves cumulative live-birth rate in ovarian stimulation for freeze-all in vitro fertilization/intracytoplasmic sperm injection cycles. Front Endocrinol (Lausanne), 2021; 12:708247.
Eser A, et al. Dual trigger with gonadotropin-releasing hormone and human chorionic gonadotropin for poor responders. J Turk Ger Gynecol Assoc. 2018;19(2):98–103.
doi: 10.4274/jtgga.2017.0045
Zhang J, et al. Dual trigger of final oocyte maturation in poor ovarian responders undergoing IVF/ICSI cycles. Reprod Biomed Online. 2017;35(6):701–7.
doi: 10.1016/j.rbmo.2017.09.002
Bourdon M, et al. Gonadotropin-releasing hormone agonist (alone or combined with human chorionic gonadotropin) vs. human chorionic gonadotropin alone for ovulation triggering during controlled ovarian stimulation for in vitro fertilization/intracytoplasmic sperm injection: a systematic review and meta-analysis. F&S Reviews. 2021; 2(4): 353–370.
Haas J, et al. Standard human chorionic gonadotropin versus double trigger for final oocyte maturation results in different granulosa cells gene expressions: a pilot study. Fertil Steril, 2016. 106(3): 653–659 e1.
Zilberberg E, et al. Co-administration of GnRH-agonist and hCG, for final oocyte maturation (double trigger), in patients with low proportion of mature oocytes. Gynecol Endocrinol. 2015;31(2):145–7.
doi: 10.3109/09513590.2014.978850
Herbemont C, et al. Dual trigger with gonadotropin-releasing hormone agonist and hCG to improve oocyte maturation rate. Gynecol Obstet Fertil Senol. 2019;47(7–8):568–73.
pubmed: 31271894
Ben-Haroush A, et al. Does ‘dual trigger’ increase oocyte maturation rate? J Obstet Gynaecol. 2020;40(6):860–2.
doi: 10.1080/01443615.2019.1674791
Lin MH, et al. Dual trigger with gonadotropin releasing hormone agonist and human chorionic gonadotropin significantly improves live birth rate for women with diminished ovarian reserve. Reprod Biol Endocrinol. 2019;17(1):7.
doi: 10.1186/s12958-018-0451-x
Chern CU, et al. Dual-trigger improves the outcomes of in vitro fertilization cycles in older patients with diminished ovarian reserve: a retrospective cohort study. PLoS One, 2020. 15(7): p. e0235707.
Albeitawi S, et al. Dual trigger with gonadotropin-releasing hormone agonist and human chorionic gonadotropin significantly improves oocyte yield in normal responders on GnRH-antagonist cycles. JBRA Assist Reprod. 2022;26(1):28–32.
pubmed: 34463444
pmcid: 8769195
Castillo JC, Garcia-Velasco J, Humaidan P. Empty follicle syndrome after GnRHa triggering versus hCG triggering in COS. J Assist Reprod Genet. 2012;29(3):249–53.
doi: 10.1007/s10815-011-9704-8